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Orexin A and orexin B are hypothalamic neuropeptides initially identified as endogenous 
ligands for two orphan G-protein coupled receptors (GPCRs). They play critical roles in the 
maintenance of wakefulness by regulating function of monoaminergic and cholinergic neurons 
that are implicated in the regulation of wakefulness. Loss of orexin neurons in humans is 
associated with narcolepsy, a sleep disorder characterized by excessive daytime sleepiness and 
cataplexy, further suggesting the particular importance of orexin in the maintenance of the 
wakefulness state. These findings have encouraged pharmaceutical companies to develop drugs 
targeting orexin receptors as novel medications of sleep disorders, such as narcolepsy and 
insomnia. Indeed, phase III clinical trials have been completed last year of suvorexant, a 
non-selective (dual) antagonist for orexin receptors, for the treatment of primary insomnia, and 
demonstrate promising results. The New Drug Application (NDA) for suvorexant has been 
submitted to the US FDA. Thus, the discovery of a critical role played by the orexin system in 
the regulation of sleep/wakefulness has opened the door of a new era for sleep medicine. 
 
1 Introduction 
Recent studies have established that the orexin (hypocretin) system is a critical regulator of 
sleep/wake states and that its deficiency results in the sleep disorder narcolepsy in humans[1]. 
These findings have brought about the possibility of novel therapies targeting the orexin system 
for sleep disorders, such as narcolepsy and insomnia. In this article, we will first review the 
evidence that the orexin system is involved in the control of sleep/wakefulness states and how 
dysfunction of the system is involved in the development of sleep disorders, such as narcolepsy 
and insomnia. Then, we will briefly go through the potential of orexin receptor agonists for 
treating disorders characterized by excessive sleepiness, including narcolepsy. We will then 
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discuss the antagonists of orexin receptors that are in development for the treatment of sleep 
disorders, and their likely future place in therapy.  
 
2 Discovery of Orexin Peptides 
Orexin A and orexin B were initially identified as endogenous ligands for two orphan G-protein 
coupled receptors (GPCR)[2]: GPCRs for which endogenous ligands are unknown are referred to 
as ‘orphan’ GPCRs. Molecular cloning studies showed that both orexin A and orexin B are 
derived from a common single precursor peptide, prepro-orexin[2]. Since intracerebroventricular 
(ICV) injection of these peptides into rats acutely stimulated food consumption, they were 
named orexin A and orexin B after the Greek word ‘orexis’, meaning appetite[2]. A messenger 
RNA (mRNA) encoding the same precursor peptide of hypocretin 1 (corresponding to orexin 
A) and hypocretin 2 (orexin B) was independently identified by de Lecea et al. as a 
hypothalamus-specific transcript[3]. Orexin A and orexin B constitute a novel distinct peptide 
family. Orexin A is a 33-amino acid peptide with an N-terminal pyroglutamyl residue, two 
intrachain disulphide bonds and C-terminal amidation, while orexin B is a 28-amino acid, 
C-terminally amidated linear peptide. The C-terminal half of orexin B is very similar to that of 
orexin A, whereas the N-terminal half is more variable. 
The actions of orexins are mediated by two receptors, named orexin 1 receptor 
(OX1R) and orexin 2 receptor (OX2R) [also known as HCRTR1 and HCRTR2]. OX1R shows 
higher affinity for orexin A than orexin B by one-order, while OX2R binds orexin A and orexin 
B with similar affinities[2]. Both receptors are Gq-coupled and caused strong excitatory effects 
on neurons examined thus far[1]. 
 Neurons expressing orexins (orexin neurons) are distributed within the perifornical 
lateral hypothalamus and send projections throughout the brain and spinal cord[2-7]. The number 
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of these neurons has been estimated as around 3,000 ~ 4,000 in rat brains and 70,000 in human 
brains[8, 9]. Consistent with the broad projections of orexin neurons, OX1R and OX2R show 
partly overlapping but distinct distributions of their mRNA throughout the CNS[10, 11]. 
 
3 Implication of Orexins in the Pathophysiology of Narcolepsy 
Human narcolepsy is a debilitating neurological disease that affects approximately 1 in 2,000 
individuals in the USA[1, 12, 13]. Onset of the condition usually occurs during adolescence. 
Narcolepsy is characterized by excessive daytime sleepiness that often results in ‘sleep attacks’ 
(sudden onset of non-rapid eye movement [REM] sleep), cataplexy (sudden bilateral skeletal 
muscle weakening triggered by emotions without impairment of consciousness), hypnagogic 
hallucinations and sleep paralysis. These symptoms can be divided into two independent 
pathological phenomena. One is the inability to maintain consolidated wakefulness and sleep 
episodes (i.e. dysregulation of transitions between wakefulness and non-REM sleep). This 
phenomenon manifests clinically as excessive daytime sleepiness (or sleep attacks) and 
disrupted night-time sleep. The other key phenomenon is the pathological intrusion of REM 
sleep into wakefulness or at sleep onset (i.e. dysregulation of REM sleep onset). It is during 
these periods that patients may experience cataplexy, hypnagogic hallucinations and sleep 
paralysis. 
 The first indications that orexins are involved in narcolepsy came from two 
independent studies utilizing dog forward genetics and mouse reverse genetics. Orexin 
knockout mice display symptoms strikingly similar to human narcolepsy, including markedly 
decreased duration of wakefulness episodes during the dark phase (i.e. inability to maintain a 
long awake period, or sleepiness), and abrupt behavioural arrests with muscle atonia (i.e. 
potentially cataplexy)[14]. Orexin neuron-ablated mice and OX1R/OX2R double-deficient mice 
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also exhibit similar phenotypes[15, 16]. In addition, mutations in the OX2R gene have been 
demonstrated to be responsible for an inherited canine model of narcolepsy[17]. This canine 
model also displays emotionally triggered cataplexy, fragmented sleep patterns and excessive 
daytime sleepiness. These studies in animals established that genetic disruption of the orexin 
system, especially that of the OX2R-mediated pathway, causes narcolepsy. 
 Subsequently, disruptions of the orexin system in human narcolepsy were confirmed. 
In contrast to normal control individuals, approximately 90 % of patients with narcolepsy with 
cataplexy have low or undetectable levels of orexin neuropeptides in the cerebrospinal fluid 
(CSF)[18]. Drastic reductions of orexin mRNA and immunoreactivity in postmortem brains of 
narcoleptic patients were also shown[9, 19]. A recent finding showing concomitant loss of 
dynorphin, neuronal activity-regulated pentraxin and orexin, which all co-localize in orexin 
neurons, strongly indicates a selective loss of orexin neurons in narcolepsy[20]. Taken in 
conjunction with a strong association of human narcolepsy with certain human leukocyte 
antigen (HLA) alleles[21], narcolepsy is likely to be caused by a selective autoimmune 
degeneration of orexin neurons. An increasing number of patients with a milder form of typical 
narcolepsy, with daytime sleepiness and sleep-onset REM periods but without cataplexy, are 
being recognized[13]. In contrast to narrowly defined narcolepsy by the presence of cataplexy, 
most (>75 %) people diagnosed with narcolepsy without cataplexy have normal CSF orexin-A 
levels[18, 22]. 
 
4 Regulation of Sleep/Wakefulness by Orexin Peptides 
Sleep and wakefulness are controlled by a complex network of neurotransmitters and 
neuromodulators, such as glutamate, GABA, glycine, serotonin, dopamine, noradrenaline 
(norepinephrine), histamine, acetylcholine, adenosine, neuropeptides, cytokines and 
 6 
prostaglandins[23, 24]. Monoaminergic neurons, including locus coeruleus (LC) noradrenergic, 
dorsal and median raphe serotonergic, and tubelomammilary nucleus (TMN) histaminergic 
neurons, project diffusely to the cerebral cortex, thalamus and brainstem, and are thought to 
promote arousal. They are highly active during wakefulness, while they reduce their activities 
during non-REM sleep and almost cease discharge during REM sleep. In contrast, 
GABA/galaninergic neurons in the ventrolateral preoptic nucleus (VLPO) of the hypothalamus 
are active during sleep, especially during non-REM sleep, and are considered as a sleep centre. 
VLPO neurons and monoaminergic neurons reciprocally inhibit each other. 
Orexin neurons send their projections densely to nuclei involved in 
sleep/wakefulness regulation, including the LC noradrenergic, raphe serotonergic, TMN 
histaminergic, pedunculopontine tegmental nucleus (PPT)/laterodorsal tegmental nucleus (LDT) 
and basal forebrain (BF) cholinergic neurons[6, 14, 25, 26]. In accordance with the innervation, 
neurons in these nuclei express OX1R and/or OX2R in different combinations[10, 11]. ICV 
administration of orexin-A in rodents reduces REM and non-REM sleep, and increases 
wakefulness[11, 27]. Furthermore, optogenetic excitation of orexin neurons results in increases in 
the probability of an awakening event during both non-REM and REM sleep[28]. Application of 
orexin A directly into the LC[29], TMN[30], BF cholinergic area[31] and LDT[32] has also been 
reported to increase wakefulness. In vitro slice electrophysiology studies have shown that 
orexin A and orexin B increase firing rates of monoaminergic neurons in the LC[25, 33], dorsal 
raphe[34, 35], TMN[26, 36, 37] and cholinergic neurons in the BF and LDT[38, 39]. These observations 
suggest that orexin neurons stabilize wakefulness by regulating these monoaminergic and 
cholinergic neurons. In addition, orexin neurons activate themselves directly and indirectly via 
local glutamatergic neurons, forming positive-feedback circuits that may stabilize the activity of 
the orexin neuron network[40, 41]. 
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Considering symptoms of narcolepsy, orexin neurons are expected to be active 
during wakefulness and to be silent during sleep, as observed in wake-active monoaminergic 
neurons. In vivo single-unit recordings have confirmed such a wake-active firing pattern of 
orexin neurons[42-44]. 
Orexin neurons have been demonstrated to have unorthodox synaptic input 
organization[45]. They are controlled primarily by excitatory synaptic inputs, which outnumber 
inhibitory synapses by a ratio of 10 : 1. This organization is in sharp contrast to the fact that 
neuronal cell bodies in the CNS are either dominated by inhibitory inputs (long-projective 
neurons), or have an approximate ratio of excitatory to inhibitory inputs of 1 : 1. Such a unique 
input organization of orexin neurons may be a necessary element for the maintenance of a low 
threshold for arousal and alertness. On the other hand, this circuitry may also be an underlying 
cause of insomnia. 
 
5 Clinical Potential of Drugs Targeting Orexin Receptors 
5.1  Orexin Receptor Agonists 
Because narcolepsy is a condition of orexin deficiency, replacement therapy using orexin 
receptor agonists could be valuable for treating narcolepsy. These drugs might also be effective 
in other conditions of excessive daytime sleepiness. Currently, excessive sleepiness is treated 
using psychostimulants, while cataplexy is treated with antidepressants[13]. To consolidate 
nocturnal sleep, improve daytime alertness and to reduce cataplexy, !-hydroxybutyrate (sodium 
oxybate, GHB) is also used[13]. However, these therapeutic regimens are problematic due to 
limited effectiveness, undesirable side effects such as insomnia or symptom rebound, and the 
potential for drug abuse[13]. Interestingly, amphetamine abuse is rare in narcoleptic patients with 
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cataplexy[13], which seems relevant to the fact that orexin signalling potentiates the mesolimbic 
dopamine pathway[1]. 
Indications that treatment of narcolepsy with orexin agonists would be effective 
come from a study demonstrating that chronic overproduction of orexin peptides from an 
ectopically expressed transgene prevented the development of a narcolepsy syndrome in orexin 
neuron-ablated mice[46]. Acute ICV administration of orexin A also maintained wakefulness, 
suppressed sleep and inhibited cataplectic attacks in orexin neuron-ablated mice[46]. These 
findings provide strong evidence of the specific causal relationship between the absence of 
orexin peptides and the development of the narcolepsy syndrome. They further indicate that 
even after substantial periods of orexin deficiency, the neural mechanisms required for 
orexin-mediated arousal and suppression of cataplexy remain intact. Nevertheless, development 
of small-molecule orexin agonists has not yet been reported. 
 
5.2  Orexin Receptor Antagonists 
Since orexins have been implicated in the maintenance of arousal, orexin receptor antagonists 
have been drawing attention in the medical field as potential new drugs for treating primary 
insomnia[1, 47]. Some pharmaceutical companies have developed several orexin receptor 
antagonists with different pharmacological characteristics, and some of them have been entered 
into late phases of clinical trials (Table 1). 
 Insomnia is a common clinical problem that has numerous impacts on individuals 
and society: 10–20 % of people have chronic insomnia, i.e. persistent trouble sleeping more 
than three nights each week[47]. People with insomnia often have difficulty initiating or 
maintaining sleep, leading to daytime fatigue, inattention and poor mood. As a result, they have 
reduced productivity, higher rates of missing work and increased risk of depression or substance 
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abuse. Insomnia is common in people with psychiatric disorders including depression, anxiety, 
dementia and substance abuse, as well as disorders that disrupt sleep such as pain, sleep apnoea, 
restless legs syndrome and circadian rhythm disorders. In some cases, however, the insomnia 
has no obvious medical or psychiatric cause and is considered primary insomnia. 
 Currently, benzodiazepine receptor agonists (BzRAs) are the most frequently 
prescribed drugs for treating primary insomnia[47]. BzRAs are positive allosteric modulators of 
GABAA receptors and widely inhibit neuronal activity. They include traditional 
benzodiazepines (e.g. lorazepam, diazepam) and non-benzodiazepines (e.g. zolpidem, zaleplon). 
Classical benzodiazepines non-selectively bind to GABAA receptors containing a !2 subunit, 
whereas non-benzodiazepine hypnotics bind with higher relative affinity to "1-containing 
receptors. BzRAs often hasten the onset of sleep, reduce the frequency of arousal during sleep 
and increase the total amount of sleep. However, since GABA is the primary inhibitory 
neurotransmitter in the brain, involved in the regulations of every aspect of the brain’s functions, 
treatment of insomnia with BzRAs is often accompanied by adverse effects, such as next-day 
residual sedation, amnestic effects, rebound insomnia, and abuse and physical dependence. 
Thus, it is preferred to use BzRAs for the short-term treatment of insomnia, taken intermittently 
and at the lowest effective dose. 
 In contrast to GABA, orexins are dedicated mainly to the promotion and 
maintenance of wakefulness. Thus, orexin antagonism may provide a novel strategy for the 
treatment of insomnia with fewer adverse effects. The first proof-of-concept of this strategy was 
demonstrated with almorexant (ACT-078573, Actelion Pharmaceuticals LtdAllschwil, 
Switzerland) [Table 1][48]. Almorexant blocks both OX1R and OX2R with almost equimolar 
potency (dual orexin receptor antagonist, DORA), is bioavailable with oral dosing and is highly 
selective to orexin receptors[48]. It reduces time spent in wakefulness and enables and maintains 
sleep in rats, dogs and humans[48, 49]. Recently, the results of a phase II study of 161 patients with 
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primary insomnia were reported[50]. The drug significantly improved the primary parameter of 
sleep efficiency, objective latency to persistent sleep and wake after sleep onset (WASO), in a 
dose-dependent manner. As compared with placebo treatment, 400 mg of almorexant given just 
before the sleep period significantly increased sleep efficiency (+14.4 %), and significantly 
decreased latency to persistent sleep (–18 min) and WASO (–54 min) on treatment nights. 
Notably, subjective sleep qualities were also significantly improved by almorexant. Effective 
doses of almorexant did not cause any relevant negative effects on next-day performance, as is 
commonly observed with current insomnia treatments such as BzRAs. As expected, almorexant 
slightly increases time spent in REM sleep, and slightly shortened the latency to enter REM 
sleep. Importantly, however, almorexant was well tolerated with no signs of cataplexy, 
hypnagogic hallucinations and sleep paralysis, suggesting that acute and short-lived blockade of 
orexin receptors does not cause narcolepsy-like symptoms. Since 2008, Actelion and 
GlaxoSmithKline (GSK) have been conducting phase III studies with almorexant. However, in 
January 2011, they discontinued these studies due to the occurrence of adverse effects ,[63] which 
are irrelevant to the function of the orexin system.  
 GSK initially focused on the development of OX1R-selective antagonists: 
SB-334867 is the first among such compounds and among entire orexin receptor antagonists[51, 
52], followed by SB-408124, SB-410220 and SB-674042[53]. These OX1R-selective antagonists 
may have the potential for treating obesity, drug addiction and panic disorder[1]. GSK also 
developed SB-649868[54], a dual OX1R/OX2R antagonist that has been reported to promote 
REM and non-REM sleep in rats and marmosets and its phase II clinical trial has been 
completed[64]  (Table 1). Importantly, this compound has been demonstrated in healthy humans 
to exert hypnotic activity without inducing noticeable changes in the EEG power density of 
non-REM sleep, which is in clear contrast to BzRAs that alter the non-REM sleep EEG, 
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confirming that sleep induced by OX1R/OX2R antagonists has a feature very similar to that of 
spontaneous sleep[55]. 
 Merck has developed a series of antagonists for orexin receptors in several distinct 
structural classes[47]. Among them, suvorexant (MK-4305) is the most advanced in terms of 
clinical pharmacology. Suvorexant is a compound from the diazepane series with a selective 
and potent DORA activity (Table 1)[56]. Two pivotal phase III efficacy trials for suvorexant have 
been completed [65,66]. According to the announcement by Merck in June, 2012[67] , suvorexant 
significantly reduced the time it took primary insomnia patients to fall asleep and increased the 
time that patients stayed asleep as early as the first night and after daily dosing for 3 months 
compared with placebo (1,021 patients in trial 1 and 1,009 patients in trial 2). The endpoints for 
the studies included both subjective and objective measures of sleep onset and sleep 
maintenance. At 3 months in trials (383 and 387 patients were treated with the high dose at 30 
or 40 mg, and 384 and 383 patients were treated with placebo in trials 1 and 2, respectively), 
daily suvorexant significantly reduced latency to persistent sleep ("10.3 and "21.7 min in trials 
1 and 2, respectively) and WASO ("38.4 and "42.0 min in trials 1 and 2, respectively) as 
compared with placebo treatment. Neither serious drug-related adverse events nor significant 
next-day objective residual effects were observed. Furthermore, no rebound insomnia of clinical 
concern was reported upon stopping suvorexant. Importantly, as in the case of almorexant, no 
sign of narcolepsy-like symptoms, such as cataplexy, was observed. The New Drug Application 
(NDA) for suvorexant has been accepted by the US FDA and is awaiting approval[72]. In 
addition, Merck has further developed MK-6096[57], which is another structurally distinct, 
piperidine-derived, dual OX1R/OX2R antagonist and its phase II clinical studies for insomnia 
have been completed[68] (Table 1). 
 Emergence of suvorexant and other orexin-based hypnotics does not mean the end of 
BzRAs, which globally reduce brain activity. Some patients, for example those with acute sleep 
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problems due to, for instance, traumatic incident, may still prefer their use, since BzRAs are 
more powerful than suvorexant in terms of promoting sleep. But in chronic primary insomnia, 
suvorexant may be the better choice as it promotes more natural sleep without serious adverse 
events. In addition, suvorexant is unlikely to have any addictive qualities, because blockade of 
orexin signalling will be expected to rather reduce mesolimbic dopaminergic tone[1]. 
 Orexin receptor antagonists that have entered into clinical studies thus far are all dual 
OX1R/OX2R antagonists. On the other hand, there is controversy regarding whether 
OX2R-selective antagonists may be better hypnotics as compared with dual antagonists. A 
study reported that an OX2R selective antagonist JNJ-10397049, developed by Johnson & 
Johnson, has better ability to promote non-REM sleep than the dual antagonist almorexant in 
rats[58]. In contrast, another recent study led to a different conclusion. It reported that an 
OX1R-selective antagonist SB-334867 produces small increases in REM and non-REM sleep, 
and an OX2R-selective antagonist EMPA, developed by Hoffmann-La Roche, produces a 
significant increase in non-REM sleep[59]. But administration of almorexant increases non-REM 
sleep more than these subtype-selective antagonists, leading to the conclusion that dual orexin 
receptor antagonism is more effective for sleep promotion than subtype-selective antagonism[59], 
although the difference in the capabilities of these drugs to cross the blood-brain barrier might 
influence their effectiveness. The latter view of the superiority of dual antagonists is also 
consistent with the conclusion derived from studies using subtype-specific knockout mice that 
OX2R plays a pivotal role, but OX1R has additional effects on promotion of wakefulness[11, 16]. 
The gating of REM sleep is likely to crucially involve both receptors, and deletions of both 
receptors are required for frequent occurrence of cataplexy in mice. From this point of view, 
OX2R-selective antagonists may have a lower risk to cause cataplexy when taken by insomnia 
patients. However, this point seems dispensable since, as a matter of fact, clinical trials have 
shown that daily dosing of dual antagonists at night does not cause cataplexy. Cataplexy may be 
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a pathological condition that emerges after almost complete loss of orexin signalling for a 
prolonged period, as in the case of human narcolepsy. In any case, further studies are needed to 
answer whether OX2R-selective antagonists are better hypnotics or not. 
 Where are the action sites of the orexin receptor antagonists for their anti-insomnia 
effects? As described above, pharmacological application of orexin peptides activate 
wake-active monoaminergic and cholinergic neurons[1]. However, which neurons among them 
play important roles in the regulation of physiological sleep/wakefulness by endogenous orexins 
in vivo have remained uncertain. Histaminergic neurons in the TMN, which express OX2R 
exclusively[11], may be a candidate of such neurons, since histamine-1 receptor is required for 
arousal effects of ICV orexin-A administration[26, 30] and OX2R expression in the posterior 
hypothalamus including the TMN rescues sleepiness in narcoleptic OX2R-deficient mice[60]. On 
the other hand, optogenetic activation of orexin neurons promotes wakefulness in mice lacking 
histamine[61], denying roles of histaminergic neurons as an efferent pathway of orexin neurons. 
Instead, activity of noradrenergic neurons in the LC has been reported to be required for the 
arousal effect of optogenetic stimulation of orexin neurons, suggesting these neurons as another 
candidate efferent pathway[62]. However, this perspective is challenged by the fact that mice 
lacking OX1R, the subtype exclusively expressed by LC noradrenergic neurons[11], do not show 
any overt abnormality of sleep/wakefulness[16]. Of course, since orexin receptors are expressed 
throughout the brain, orexin antagonists may exert their anti-insomnia effects by acting on brain 
regions other than the TMN and LC, and also by binding to multiple sites involved in 
sleep/wake regulation. Future studies by means of focal administrations of orexin receptor 




The discovery of a critical role played by the orexin system in the regulation of 
sleep/wakefulness has opened the door of a new era for sleep medicine. Orexin receptor 
antagonists appear to have a good chance of success as a new medication for primary insomnia, 
as demonstrated by almorexant and suvorexant. On the contrary, for treating daytime sleepiness 
such as narcolepsy, development of bioavailable orexin receptor agonists is awaited. Allosteric 
enhancers for orexin receptors may be satisfactory as a novel medication of daytime sleepiness 
caused by reasons other than the loss of orexin neurons. In the case of agonists/enhancers, 
however, potential risk of addiction should be taken into account, since orexin signalling 
potentiates the mesolimbic dopamine pathway[1]. Lastly, given that the orexin system controls 
wakefulness through interactions with systems regulating emotion, reward and energy 
homeostasis, agonists and antagonists for orexin receptors may have a potential for novel 
treatment of other pathological conditions such as panic disorder, obesity and drug addiction[1]. 
It should be also noted that phase II trials are investigating the safety and efficacy of MK-6096 
for migraine prophylaxis, major depression and painful diabetic neuropathy.[69] 
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